SLAS Recognizes Paul Hung, Ph.D. of COMBiNATi, Inc. With Innovation Award at SLAS2018
News Feb 11, 2018
SLAS recognized Paul Ju Sung Hung, PhD of COMBiNATi, Inc. this afternoon at SLAS2018 in San Diego, CA with the SLAS Innovation Award. Hung received the award as recognition of his exceptional podium presentation at the SLAS Annual Conference, Microfluidic Siphoning Array (MSA) – A Novel Scalable Digital PCR Integrated Platform. Hung accepted a $10,000 cash prize as part of one of the highest honors given at the conference.
Each year, SLAS Innovation Award finalists are identified based on their submitted abstracts which demonstrate exceedingly innovative research and discovery in life sciences and contribute to the exploration of technologies in the laboratory, exceed a benchmark or milestone in screening or the lead discovery process, or demonstrate an advanced and integrated use of mature technologies. The award finalist is then selected by a panel of judges who attend and score each podium presentation on the impact the work has on life sciences and technology, originality and creativity, quality of the science, and the oral presentation.
Ten 2018 SLAS Innovation Award finalists were selected to compete for this year’s cash prize, and Hung was announced as the winner at the closing ceremony and keynote presentation at SLAS2018 today. In addition to Hung, the other nine finalists who presented their work throughout the week at SLAS2018 are as follows:
Santiago Costantino, University of Montreal
Optical tools for single-cell manipulations and sequencing
Dennis Eastburn, PhD, Mission Bio Inc.
High-throughput single-cell DNA sequencing of AML tumors with droplet microfluidics
Olivier Frey, PhD, InSphero
Automating multi-tissue microphysiological systems using 3D microtissues
Rajarshi Guha, PhD, National Institutes of Health
Pharos – A Torch to Use in Your Journey In the Dark Genome
Shane Horman, PhD, Genomics Institute of the Novartis Research Foundation
An Ultra High-Throughput 3D Assay Platform for Evaluating T-cell-Mediated Tumor Killing
Transon V. Nguyen, Notable Labs
Combinatorial Drug Screening, High-Throughput Flow Cytometry, and Agile Integration: a Modern Platform for Personalized Treatment Discovery for Cancer Patients
Amy Rowat, BSc, MSc, PhD, University of California, Los Angeles
Label-free prediction of cancer cell invasion by single-cell physical phenotyping
Kevin Tsia, PhD, The University of Hong Kong
Ultrafast all-optical laser-scanning imaging - Enabling deep single-cell imaging and analysis
Julea Vlassakis, University of California, Berkeley/UCSF Joint Graduate Program in Bioengineering
Electrophoretic Cytometry Isolates Cytoskeleton Molecular Complexes of Single Cancer Cells
SLAS2018 showcased scientific advances and state-of-the-art applications of new technologies via 144 podium presentations, 350+ poster presentations, 300+ multinational exhibitors, 20 short courses, a menu of personalized career services and an abundance of intelligent network-building opportunities.
An FDA-approved drug has been identified that, when used with surgery, hampers metastasis in an animal model. Originally developed and approved ~65 years ago to control blood pressure, the medication resperine also prevents what are known as tumor-derived extracellular vesicles from fusing to healthy cells and sharing their cargo of disease-promoting molecules.READ MORE